Literature DB >> 30723111

Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.

Naranie Shanmuganathan1,2,3,4,5,6, Susan Branford3,5,6,7,8, Timothy P Hughes1,2,4,5,6, Devendra Hiwase1,2,4,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30723111      PMCID： PMC6373740          DOI： 10.1182/bloodadvances.2018027516

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  21 in total

1.  Inhibition of c-Kit by tyrosine kinase inhibitors.

Authors:  Allison Galanis; Mark Levis
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

2.  The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.

Authors:  Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Journal:  Leuk Lymphoma       Date:  2005-07

3.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

4.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

5.  Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.

Authors:  Carlos E Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; L Jeffrey Medeiros; Hagop Kantarjian
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

Review 6.  Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Michael Steinberg
Journal:  Clin Ther       Date:  2007-11       Impact factor: 3.393

7.  Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.

Authors:  G Buesche; R Hehlmann; H Hecker; H Heimpel; B Heinze; A Schmeil; M Pfirrmann; G Gomez; A Tobler; H Herrmann; M Kappler; J Hasford; T Buhr; H-H Kreipe; A Georgii
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

8.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

Authors:  Amy D Klion; Jamie Robyn; Cem Akin; Pierre Noel; Margaret Brown; Melissa Law; Dean D Metcalfe; Cynthia Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

10.  TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Authors:  David T Yeung; Michael P Osborn; Deborah L White; Susan Branford; Jodi Braley; Alan Herschtal; Michael Kornhauser; Samar Issa; Devendra K Hiwase; Mark Hertzberg; Anthony P Schwarer; Robin Filshie; Christopher K Arthur; Yiu Lam Kwan; Judith Trotman; Cecily J Forsyth; John Taper; David M Ross; Jennifer Beresford; Constantine Tam; Anthony K Mills; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2014-12-17       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.